Literature DB >> 6426781

Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture.

M J Ehrke, K Ryoyama, S A Cohen.   

Abstract

The cellular basis for the augmented cell-mediated cytotoxic (CMC) response seen when spleen cells from Adriamycin (ADM)-treated mice were stimulated in culture was investigated. Under conditions where mature macrophages were reduced (adherent or silica-sensitive cells removed) at time of alloantigen challenge, the cells from ADM-treated mice developed levels of CMC activity much higher than the low levels which were developed by similar subsets of cells from nontreated control mice. This indicates that ADM treatment enriched a subset of cells in spleen which was nonadherent, silica-insensitive, and nonphagocytic but was capable of providing accessory function. When mature macrophages were not removed, the capability to develop an augmented level of CMC was shown to be associated with a subset of cells from ADM-treated mice which was adherent to either plastic or nylon wool. In recombination experiments, it was found that the removal of Thy 1.2+ cells from the adherent subset from ADM-treated mice had little effect on the response, while their removal from the adherent subset from nontreated mice resulted in elevated levels of response. A similar effect was obtained when Lyt 2.2+ cells were eliminated but not when Lyt 1.2+ cells were removed. This indicates that a Thy 1.2+, Lyt 1-2+ cell, involved in regulation of the response, was missing from or failed to function in the ADM-treated population. Based on these findings, ADM apparently induces modifications in two cell subsets: (a) immature cells of the monocyte/macrophage lineage which can provide accessory function; and (b) adherent, Lyt 2+ T-cells which cooperate in maintaining levels of CMC activity at "normal" levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426781

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells.

Authors:  Daeho Cho; Young-In Kim; Jae Seung Kang; Eunsil Hahm; Yoolhee Yang; Daejin Kim; Seonghan Kim; Yeong Seok Kim; Daeyoung Hur; Hyunjeong Park; Young Il Hwang; Tae-Sung Kim; Wang Jae Lee
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

2.  RNA recovery efficiency for cultured cells and organ-derived cell suspensions.

Authors:  E S Berleth; B J Dolnick; M J Ehrke; E Mihich
Journal:  Nucleic Acids Res       Date:  1994-05-25       Impact factor: 16.971

3.  Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin.

Authors:  Z Y Xu; M Hosokawa; K Morikawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

5.  Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.

Authors:  D L Maccubbin; S A Cohen; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.

Authors:  Hazem Ghebeh; Cynthia Lehe; Eman Barhoush; Khaldoon Al-Romaih; Asma Tulbah; Monther Al-Alwan; Siti-Faujiah Hendrayani; Pulicat Manogaran; Ayodele Alaiya; Taher Al-Tweigeri; Abdelilah Aboussekhra; Said Dermime
Journal:  Breast Cancer Res       Date:  2010-07-13       Impact factor: 6.466

7.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  Cytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.

Authors:  S A Huber; A Moraska
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

9.  A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma.

Authors:  T Akiyoshi; S Arinaga; K Takamuku; T Wada; F Koba; H Tsuji
Journal:  Jpn J Surg       Date:  1988-09

10.  Immunodepressive activity of FCE 23762 on humoral and cell-mediated immune responses in normal mice: comparison with doxorubicin.

Authors:  M C Fornasiero; M Ferrari; P Gnocchi; D Trizio; A M Isetta
Journal:  Agents Actions       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.